Dapagliflozin - CAS 461432-26-8
Catalog number:
461432-26-8
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
SGLT
Description:
Dapagliflozin(BMS512148) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2) is in development for the treatment of type 2 diabetes mellitus (T2DM).
Publictions citing BOC Sciences Products
  • >> More
Purity:
0.98
Appearance:
White to Off-White Solid
Synonyms:
Dapagliflozin; trade name Farxiga in the US and Forxiga in the EU.
MSDS:
Inquire
1.Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin.
Schwartz SS1, Katz A2. Diabetes Metab Syndr Obes. 2016 Mar 15;9:71-82. doi: 10.2147/DMSO.S65588. eCollection 2016.
In type 2 diabetes (T2D), early combination therapy using agents that target a number of the underlying pathophysiologic defects contributing to hyperglycemia may improve patient outcomes. For many patients, the combination of metformin with a sodium-glucose cotransporter-2 (SGLT-2) inhibitor may be a good option because these agents have complementary mechanisms of action, neutral-to-positive effects on body weight, and a low risk of hypoglycemia. This review focuses on the combination of metformin with dapagliflozin, a member of the SGLT-2 inhibitor class of antidiabetes agents. In clinical trials, the combination of dapagliflozin with metformin produced significant and sustained reductions in glycated hemoglobin and body weight in a broad range of adult patients with T2D, including those initiating pharmacotherapy and those with more advanced disease. These reductions were accompanied by modest decreases in blood pressure. Dapagliflozin as add-on therapy to metformin was well tolerated and associated with low rates of hypoglycemia.
2.Sodium-Glucose Cotransporter-2 Inhibitors and Genital and Urinary Tract Infections in Type 2 Diabetes.
Arakaki RF1. Postgrad Med. 2016 Mar 16. [Epub ahead of print]
Coincident with the high and increasing worldwide prevalence of type 2 diabetes (T2D), a growing armamentarium of antidiabetes medications has been introduced to target different organ systems that play a role in the pathophysiology of T2D. Among these, the sodium-glucose cotransporter-2 (SGLT-2) inhibitors were introduced in the United States in 2013 as a new treatment option to address the hyperglycemia associated with T2D. SGLT-2 inhibitors decrease renal glucose reabsorption, resulting in glucosuria, alleviation of hyperglycemia, and modest weight loss and are associated with a low risk of hypoglycemia. The SGLT-2 inhibitors have been linked to an increased incidence of genital mycotic infections and, to a lesser extent, urinary tract infections, which may limit their utility in some patients. This review examines the prevalence, recurrence rates, treatment options, and responses to treatment of genital and urinary tract infections in patients with T2D receiving SGLT-2 inhibitors, with the aim of guiding clinicians in the most effective use of these agents for the treatment of hyperglycemia.
3.Dapagliflozin in the Treatment of Patients With Type 2 Diabetes Presenting With High Baseline A1C.
Skolnik N1, Bonnes H1, Yeh H2, Katz A2. Postgrad Med. 2016 Apr 4. [Epub ahead of print]
OBJECTIVES: To evaluate the efficacy and safety of dapagliflozin 5 and 10 mg/d versus placebo in patients with type 2 diabetes and high baseline A1C defined as A1C ≥9% or ≥10%.
4.Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
Leiter LA1, Cefalu WT2, de Bruin TW3, Xu J4, Parikh S5, Johnsson E6, Gause-Nilsson I6. Diabetes Obes Metab. 2016 Mar 24. doi: 10.1111/dom.12666. [Epub ahead of print]
AIM: To evaluate the long-term efficacy, safety and tolerability of dapagliflozin versus placebo added to usual care in patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related SGLT Products


CAS 842133-18-0 Canagliflozin

Canagliflozin
(CAS: 842133-18-0)

Canagliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Canagliflozin has been shown to dose dependently reduce calculated renal threshold for gluc...

KGA2727
(CAS: 666842-36-0)

KGA2727 is a selective and potent SGLT1 inhibitor for the treatment of diabete. Its inhibition constant (Ki) values of 97 and 13,600 nM for human (h) SGLT1 and ...

CAS 903565-83-3 Tofogliflozin

Tofogliflozin
(CAS: 903565-83-3)

Tofogliflozin is an experimental drug for the treatment of diabetes mellitus and is being developed by Chugai Pharma in collaboration with Kowa and Sanofi. It i...

CAS 960404-48-2 Dapagliflozin (2S)-1,2-propanediol, hydrate

Dapagliflozin (2S)-1,2-propanediol, hydr
(CAS: 960404-48-2)

Dapagliflozin (2S)-1,2-propanediol, hydrate is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2). It is in developm...

CAS 864070-44-0 Empagliflozin

Empagliflozin
(CAS: 864070-44-0)

Empagliflozin is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6.

CAS 461432-26-8 Dapagliflozin

Dapagliflozin
(CAS: 461432-26-8)

Dapagliflozin(BMS512148) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2) is in development for the treatment o...

CAS 60-81-1 Phlorizin

Phlorizin
(CAS: 60-81-1)

Phlorizin is a 2'-glucoside of phloretin. It belongs to the group of dihydrochalcones, a type of flavonoids.

LIK066
(CAS: 1291094-73-9)

LIK066 is a potent Sodium-glucose transporter 1 and Sodium-glucose transporter 2 inhibitor originated by Novartis Pharmaceuticals Corporation IC50 value is 22.0...

CAS 1118567-05-7 EGT1442

EGT1442
(CAS: 1118567-05-7)

EGT1442 is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively. It significantly prolonged the median survival o...

Mizagliflozin
(CAS: 666843-10-3)

Mizagliflozin is a sodium-glucose transporter inhibitor. It is expected to improve postprandial hyperglycemia by suppressing glucose absorption from the intesti...

CAS 1201913-82-7 Tofogliflozin hydrate

Tofogliflozin hydrate
(CAS: 1201913-82-7)

Tofogliflozin(CSG-452) hydrate is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human...

CAS 1210344-57-2 PF-04971729

PF-04971729
(CAS: 1210344-57-2)

PF-04971729, a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2, is currently in phase 2 trials for the treatment of diabetes mell...

CAS 1018899-04-1 LX-4211

LX-4211
(CAS: 1018899-04-1)

LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.

CAS 761423-87-4 Ipragliflozin

Ipragliflozin
(CAS: 761423-87-4)

Ipragliflozin is a highly potent and selective SGLT2 inhibitor and has little and NO potency for SGLT1/3/4/5/6.

CAS 60-82-2 Phloretin

Phloretin
(CAS: 60-82-2)

hloretin is a dihydrochalcone, a type of natural phenols, which shows beneficial effects on diabetes.

CAS 928672-86-0 Canagliflozin hemihydrate

Canagliflozin hemihydrate
(CAS: 928672-86-0)

Canagliflozin hemihydrate is a highly potent and selective inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90...

CAS 647834-15-9 Atigliflozin

Atigliflozin
(CAS: 647834-15-9)

Atigliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor. It has antihyperglycemic activity and is used as an antihyperglycaemic dr...

JNJ-39933673 hemihydrate
(CAS: 1404307-42-1)

TA-1887 is a selective Sodium Glucose Cotransporter 2 Inhibitor with pronounced antihyperglycemic effects in high-fat diet-fed KK (HF-KK) mice. It may be used f...

Chemical Structure

CAS 461432-26-8 Dapagliflozin

Quick Inquiry

Verification code

Featured Items